Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2003
11/04/2003US6642359 Peptide or protein for use in the diagnosis, treatment or prophylaxis of viral disease
11/04/2003US6642358 Receptor that binds trail
11/04/2003US6642355 Endothelin-antagonizing peptide
11/04/2003US6642274 Methods and compositions for preventing and treating prostate disorders
11/04/2003US6642269 Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
11/04/2003US6642253 Thrombin inhibitors comprising an aminoisoquinoline group
11/04/2003US6642212 Health supplement comprising naturally occurring phytoestrogen selected from any two or more of genistein, daidzein and/or their glycosides
11/04/2003US6642208 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
11/04/2003US6642207 Artificial chromosome constructs containing foreign nucleic acid sequences
11/04/2003US6642204 Inhibitors of hepatitis C virus NS3 proteases; inhibit RNA replication
11/04/2003US6642203 Purified peptide from penaeid prawns, having specified molecular mass and isoelectric pH, comprising proline-rich N-terminal region and C-terminal region having 6 cysteine residues forming three intramolecular disulfide bridges
11/04/2003US6642202 Egg having active oxygen eliminating ability and method of producing same
11/04/2003US6642201 Use of a dipeptide for stimulating repair processes
11/04/2003US6642038 GlcNAc phosphotransferase of the lysosomal targeting pathway
11/04/2003US6642032 Uses of avian interferon gamma (IFN-γ)
11/04/2003US6642026 Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
11/04/2003US6642025 Chlamydia antigens and corresponding DNA fragments and uses thereof
11/04/2003US6642023 High molecular weight; encoded by isolated nucleic acid; expression vectors; use for diagnostics, prophylaxis and treatment of infections
11/04/2003US6642022 Polypeptide, encoded by recombinant nucleic acid; antagonists can be used for treatment of atherosclerosis and cancer; use for evaluating new drugs
11/04/2003US6642011 Reducing allegenic response heterologous proteins; obtain nucleotide sequences of heterologous protein, insert subtilisin sequences, transform cell, expression vector, recover protein, monitor human to protein
11/04/2003US6642010 Identifying, monitoring, and treating women for breast precancer or cancer
11/04/2003US6642008 Assays and therapies for latent viral infection
11/04/2003US6642006 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of nervous system, vision, kidney and liver disorders
11/04/2003US6641999 Probing method for identifying antibodies specific for selected antigens
11/04/2003US6641820 Treating a bone tumor, in particular pain associated with bone tumor, by administration to a patient of a therapeutically effective amount of an agent are disclosed. The agent may include a clostridial neurotoxin component attached to target
11/04/2003US6641818 Cellular proteins which mediate herpesvirus entry
11/04/2003US6641815 Sequestrin
11/04/2003US6641814 Identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, and others, polypeptides,
11/04/2003US6641813 Methods and reagents for diagnosis of autoantibodies
11/04/2003US6641812 Heat shock protein-based vaccines and immunotherapies
11/04/2003US6641811 Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
11/04/2003US6641810 Methods of using geldanamycin and FK506 to treat peripheral nerve damage
11/04/2003US6641809 Method of regulating cellular processes mediated by B7 and CD28
11/04/2003US6641807 Helper dependent adenoviral vectors encoding erythropoietin provide high levels of epo to achieve a long-term therapeutically effective dosage, and allow for repeat administration to patients with disorders such as anaemia of
11/04/2003US6641800 Administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer soluble in the liquefied hydrofluoroalkane which is selected from polymers
11/04/2003US6641611 A coating for an intravascular implant that prevents hyperproliferative vascular disease, includes repamyicin as first agent which acts on calcium independent cellular pathway and second agent is cyclosporin A
11/04/2003CA2094773C 2,4-dioxoimidazolidine derivatives
11/04/2003CA2084677C Apo ai polypeptides, antibodies, and immunoassays
11/04/2003CA2071811C Improved meningococcal polysaccharide conjugate vaccine
11/04/2003CA2040555C Cloned glutamic acid decarboxylase
11/03/2003CA2427574A1 Plant bioreactor
10/2003
10/30/2003WO2003089934A2 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1
10/30/2003WO2003089932A1 Method for detecting the presence or risk of prostate cancer by detecting products of psa or klk2
10/30/2003WO2003089903A2 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1)
10/30/2003WO2003089669A1 Novel method of assaying nucleic acid
10/30/2003WO2003089667A1 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
10/30/2003WO2003089649A1 Expression vector comprising a signal sequence and an amino-terminal peptide tag
10/30/2003WO2003089645A1 Human cancer suppressor gene, hccs-4 and protein encoded therein
10/30/2003WO2003089638A1 Nucleic acid molecule encoding a variant ddah 1 protein and uses thereof
10/30/2003WO2003089624A2 Fc receptor homolog, reagents, and uses thereof
10/30/2003WO2003089608A2 Drg11-responsive (dragon) gene family
10/30/2003WO2003089607A2 Cell wall mannoproteins and active epitopes from candida albicans and antibodies recognizing them
10/30/2003WO2003089596A2 Novel prostate tumor-specific promoter
10/30/2003WO2003089593A2 Adjuvant enhanced immunotherapy
10/30/2003WO2003089590A2 TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
10/30/2003WO2003089588A2 Novel molecules of the pyrin/nbs/lrr protein family and uses thereof
10/30/2003WO2003089584A2 Use of parapox b2l protein to modify immune responses to administered antigens
10/30/2003WO2003089583A2 Tissue specific genes and gene clusters
10/30/2003WO2003089572A2 Essential and important genes of pseudomonas aeroginosa and the use thereof to design or identify antibacterial agents
10/30/2003WO2003089571A2 Ehrlichia canis genes and vaccines
10/30/2003WO2003089569A2 Use of il-19, il-22 and il-24 to treat hematopoietic disorders
10/30/2003WO2003089472A2 Anti-nls scfv and peptides and uses thereof in nuclear import inhibition
10/30/2003WO2003089470A1 Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases
10/30/2003WO2003089468A1 Methods and means for producing proteins with predetermined post-translational modifications
10/30/2003WO2003089459A2 Thyrotropin-releasing hormone analogues and their therapeutic applications
10/30/2003WO2003089458A2 Conjugates of membrane translocating agents and pharmaceutically active agents
10/30/2003WO2003089457A2 Peptide inhibitors of protein kinase c ϝ for pain management
10/30/2003WO2003089456A2 Peptide inhibitors of protein kinase c
10/30/2003WO2003089450A2 Fusion polypeptides and methods for inhibiting microbial adhesion
10/30/2003WO2003089418A1 Indane acetic acid derivatives and their use as pharmaceutical agents
10/30/2003WO2003089410A1 Phenylalanine derivative
10/30/2003WO2003089003A1 Methods of treatment and diagnosis of patients with hepatitis c infection
10/30/2003WO2003089002A1 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
10/30/2003WO2003089001A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
10/30/2003WO2003089000A2 Anti-hiv composition, production method thereof and medicament
10/30/2003WO2003088993A1 Thermolysin enzymatic wound debrider
10/30/2003WO2003088991A1 Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
10/30/2003WO2003088979A2 Oligonucleotides from sequences coding for the surface component of envelope proteins of primate t-cell leukaemia/lymphoma viruses (ptlv) and uses thereof
10/30/2003WO2003088976A1 Method for treating and preventing hyperparathyroidism
10/30/2003WO2003088954A1 Combination therapy for the treatment of cancer
10/30/2003WO2003088951A1 Formulation of fine particles using liquefied or dense gases
10/30/2003WO2003088950A1 System for enhanced targeted delivery
10/30/2003WO2003088935A1 Compositions and methods for inducing new hair follicle formation and hair growth in a desired orientation
10/30/2003WO2003088929A1 Method of treating onychomycosis with urea and an antioxidant
10/30/2003WO2003088926A2 Compositions and method of treating alzheimer’s disease
10/30/2003WO2003088921A2 Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
10/30/2003WO2003088920A2 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
10/30/2003WO2003088918A2 PHARMACEUTICAL COMPOSITIONS CONTAINING α3β4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE
10/30/2003WO2003088917A2 Regulation of tnf-alpha
10/30/2003WO2003088905A2 Compositions and minimally invasive methods for treating incomplete tissue repair
10/30/2003WO2003088904A2 Screening and therapeutic methods for treating circadian rhythm disorders
10/30/2003WO2003088900A2 Solid forms of salts with tyrosine kinase activity
10/30/2003WO2003088898A2 Compositions and methods for the diagnosis and treatment of tumor
10/30/2003WO2003088894A2 A multi component controlled release system for anhydrous cosmetic compositions
10/30/2003WO2003088883A1 Combination of ablation and controlled drug delivery for the tre atment of cancer
10/30/2003WO2003088812A2 Nor-1 and nur77 nuclear receptors as targets for anti-leukemia therapy
10/30/2003WO2003088760A1 Canola protein isolate compositions
10/30/2003WO2003088749A1 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
10/30/2003WO2003088748A1 Use of heme oxygenase-1 and products of heme degradation
10/30/2003WO2003060146A3 Compositions and methods relating to urinary specific genes and proteins
1 ... 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 ... 3163